John Ryan named Senior Vice President and General Counsel at Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14. Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.

Read more

Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma

Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.

Read more

Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

Read more

SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank, a Population Health Initiative for Research and Education

Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative — a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.

Read more

Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Read more

Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Read more